⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18951911 | 0.82 | — | — | |
| SCHEMBL28540134 | 0.80 | TSHR (0.41) | — | |
| SCHEMBL17200047 | 0.80 | — | — | |
| SCHEMBL15824846 | 0.77 | HDAC6 (0.52) | — | |
| SCHEMBL1268235 | 0.76 | — | — | |
| SCHEMBL19953833 | 0.75 | HDAC2 (0.33) | — | |
| SCHEMBL15819854 | 0.75 | CHRM3 (0.43) | — | |
| SCHEMBL22290 | 0.69 | — | — | |
| SCHEMBL17503288 | 0.69 | — | — | |
| SCHEMBL420951 | 0.69 | IKBKE (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122071464-A | Heterocyclic compound, pharmaceutical composition thereof and application thereof | 上海璎黎药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250011300-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4436667-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023072794-A1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| EP-3325475-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017014321-A1 | OXADIAZOLE DERIVATIVES USEFUL AS HDAC INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-26 | — | — | WO | disclosed |
| EP-3057951-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |